
CCRN Stock Forecast & Price Target
CCRN Analyst Ratings
Bulls say
Cross Country Healthcare is set to go private in a $437 million deal with Knox Lane, which presents a potential upside for the company as it becomes a privately held platform company in Knox Lane's portfolio. While the Q1/26 results showed a decline in revenue due to factors such as a normalization in demand and cost-cutting measures in the healthcare industry, the company still exceeded earnings expectations. Additionally, potential upside risks include investments in new technology and a potential surge in demand for temp healthcare workers due to a new pandemic outbreak.
Bears say
Cross Country Healthcare is facing a challenging market environment with an 18% drop in total revenues and a 130 basis point contraction in margins. While their AI-powered digital platform and recent acquisition by Knox Lane may provide some relief, there is still skepticism about their ability to recover and compete in the travel nursing market. Despite an attractive purchase price by Knox Lane, there is uncertainty around the timing and execution risks of the acquisition.
This aggregate rating is based on analysts' research of Cross Country Healthcare and is not a guaranteed prediction by Public.com or investment advice.
CCRN Analyst Forecast & Price Prediction
Start investing in CCRN
Order type
Buy in
Order amount
Est. shares
0 shares